GE HealthCare Technologies (GEHC)
Market Price (3/11/2026): $72.98 | Market Cap: $33.1 BilSector: Health Care | Industry: Health Care Equipment
GE HealthCare Technologies (GEHC)
Market Price (3/11/2026): $72.98Market Cap: $33.1 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.5% | Weak multi-year price returns2Y Excs Rtn is -54%, 3Y Excs Rtn is -72% | Key risksGEHC key risks include [1] playing catch-up to competitors in advanced technologies like photon-counting CT and [2] execution risks in successfully integrating its AI and digital transformation initiatives. |
| Low stock price volatilityVol 12M is 37% | ||
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Biopharmaceutical R&D, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 6.5% |
| Low stock price volatilityVol 12M is 37% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Digital Health & Telemedicine. Themes include Personalized Diagnostics, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -54%, 3Y Excs Rtn is -72% |
| Key risksGEHC key risks include [1] playing catch-up to competitors in advanced technologies like photon-counting CT and [2] execution risks in successfully integrating its AI and digital transformation initiatives. |
Qualitative Assessment
AI Analysis | Feedback
1. Q4 2025 Earnings Showed Margin Compression and Revenue Miss.
GE HealthCare's Q4 2025 earnings, reported on February 4, 2026, indicated a decline in profitability with the adjusted EBIT margin falling by 200 basis points year-over-year to 16.7%, and adjusted EPS decreasing by $0.01 year-over-year to $1.44. These negative impacts were primarily attributed to tariff expenses and an unfavorable product mix. Additionally, the company's reported revenue of $5.698 billion for the quarter narrowly missed analyst estimates of $5.723 billion. The management also cited a $245 million EBIT impact from tariffs for the full year 2025.
2. Persistent Macroeconomic Headwinds and Cautious Market Conditions.
The broader healthcare sector in early 2026 faced significant operational and financial pressures, including labor shortages, inflation, and supply chain volatility. US healthcare leaders expressed caution due to ongoing uncertainties surrounding tariffs, drug pricing, and regulatory changes. Providers and payers continued to experience margin pressure as medical cost trends outpaced reimbursement. GE HealthCare specifically acknowledged challenging market conditions in China.
Show more
Stock Movement Drivers
Fundamental Drivers
The -9.0% change in GEHC stock from 11/30/2025 to 3/10/2026 was primarily driven by a -7.7% change in the company's Net Income Margin (%).| (LTM values as of) | 11302025 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 79.96 | 72.73 | -9.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 20,246 | 20,625 | 1.9% |
| Net Income Margin (%) | 11.0% | 10.1% | -7.7% |
| P/E Multiple | 16.4 | 15.8 | -3.9% |
| Shares Outstanding (Mil) | 456 | 453 | 0.7% |
| Cumulative Contribution | -9.0% |
Market Drivers
11/30/2025 to 3/10/2026| Return | Correlation | |
|---|---|---|
| GEHC | -9.0% | |
| Market (SPY) | -0.9% | 38.3% |
| Sector (XLV) | -2.9% | 49.6% |
Fundamental Drivers
The -1.3% change in GEHC stock from 8/31/2025 to 3/10/2026 was primarily driven by a -10.0% change in the company's Net Income Margin (%).| (LTM values as of) | 8312025 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 73.67 | 72.73 | -1.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 19,965 | 20,625 | 3.3% |
| Net Income Margin (%) | 11.2% | 10.1% | -10.0% |
| P/E Multiple | 15.0 | 15.8 | 5.2% |
| Shares Outstanding (Mil) | 457 | 453 | 0.9% |
| Cumulative Contribution | -1.3% |
Market Drivers
8/31/2025 to 3/10/2026| Return | Correlation | |
|---|---|---|
| GEHC | -1.3% | |
| Market (SPY) | 5.3% | 44.2% |
| Sector (XLV) | 11.9% | 47.8% |
Fundamental Drivers
The -16.6% change in GEHC stock from 2/28/2025 to 3/10/2026 was primarily driven by a -20.8% change in the company's P/E Multiple.| (LTM values as of) | 2282025 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 87.19 | 72.73 | -16.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 19,671 | 20,625 | 4.8% |
| Net Income Margin (%) | 10.1% | 10.1% | -0.3% |
| P/E Multiple | 19.9 | 15.8 | -20.8% |
| Shares Outstanding (Mil) | 456 | 453 | 0.7% |
| Cumulative Contribution | -16.6% |
Market Drivers
2/28/2025 to 3/10/2026| Return | Correlation | |
|---|---|---|
| GEHC | -16.6% | |
| Market (SPY) | 15.0% | 67.8% |
| Sector (XLV) | 4.2% | 61.3% |
Fundamental Drivers
The -3.8% change in GEHC stock from 2/28/2023 to 3/10/2026 was primarily driven by a -11.9% change in the company's P/E Multiple.| (LTM values as of) | 2282023 | 3102026 | Change |
|---|---|---|---|
| Stock Price ($) | 75.63 | 72.73 | -3.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 18,341 | 20,625 | 12.5% |
| Net Income Margin (%) | 10.4% | 10.1% | -3.2% |
| P/E Multiple | 17.9 | 15.8 | -11.9% |
| Shares Outstanding (Mil) | 454 | 453 | 0.2% |
| Cumulative Contribution | -3.8% |
Market Drivers
2/28/2023 to 3/10/2026| Return | Correlation | |
|---|---|---|
| GEHC | -3.8% | |
| Market (SPY) | 77.3% | 55.4% |
| Sector (XLV) | 26.0% | 50.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| GEHC Return | - | - | 28% | 1% | 5% | -8% | 26% |
| Peers Return | 9% | -20% | 7% | 11% | 0% | -4% | 0% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -1% | 81% |
Monthly Win Rates [3] | |||||||
| GEHC Win Rate | - | - | 50% | 42% | 58% | 33% | |
| Peers Win Rate | 53% | 42% | 50% | 53% | 52% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| GEHC Max Drawdown | - | - | -4% | -7% | -25% | -9% | |
| Peers Max Drawdown | -13% | -33% | -15% | -7% | -18% | -6% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -2% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, SYK, HOLX, BAX, ISRG.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/10/2026 (YTD)
How Low Can It Go
null
nullIn The Past
null
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About GE HealthCare Technologies (GEHC)
AI Analysis | Feedback
Here are 1-3 brief analogies for GE HealthCare Technologies (GEHC):
The **Siemens** of medical imaging and diagnostics.
Like **Philips**, but focused purely on advanced hospital imaging and patient monitoring systems.
The **Johnson & Johnson** for high-tech hospital equipment like MRI scanners and patient monitors.
AI Analysis | Feedback
- Medical Imaging Systems: Manufactures advanced diagnostic imaging equipment such as MRI, CT, Ultrasound, X-ray, and Nuclear Medicine systems used for disease detection and diagnosis.
- Patient Care Solutions: Provides a range of devices for patient monitoring, anesthesia delivery, diagnostic cardiology, and maternal-infant care, crucial for clinical decision-making and patient management.
- Pharmaceutical Diagnostics: Develops and supplies contrast media and radiopharmaceuticals that enhance the clarity and diagnostic value of various medical imaging procedures.
- Software & AI Solutions: Offers a suite of enterprise software and AI-powered applications for clinical workflow optimization, data management, and operational efficiency within healthcare systems.
AI Analysis | Feedback
GE HealthCare Technologies (symbol: GEHC) primarily sells its advanced medical technology, pharmaceutical diagnostics, and digital solutions to other companies and healthcare institutions, rather than directly to individual consumers.
Given the highly diversified global customer base typical for a healthcare technology provider of its scale, GE HealthCare does not publicly disclose specific "major customers" by name in its financial filings or investor communications. This generally indicates that no single customer accounts for a significant enough portion of its revenue (e.g., 10% or more) to warrant individual disclosure under SEC regulations.
Therefore, while specific customer company names cannot be provided, GE HealthCare's major customers fall into the following broad categories of organizations:
- Hospitals and Integrated Delivery Networks: This is a primary customer segment, encompassing a wide range of healthcare facilities from large academic medical centers and multi-hospital systems to community hospitals. These customers purchase a broad spectrum of GE HealthCare's offerings, including medical imaging equipment (MRI, CT, Ultrasound, X-ray), patient monitoring systems, and healthcare software.
- Ambulatory and Outpatient Facilities: This category includes independent imaging centers, specialized clinics (e.g., cardiology, women's health), and outpatient surgery centers that utilize GE HealthCare's diagnostic and monitoring technologies.
- Pharmaceutical and Biopharmaceutical Companies: These customers primarily purchase GE HealthCare's pharmaceutical diagnostics, such as contrast media used in imaging, and solutions that support drug discovery and development processes.
- Government Healthcare Systems and Research Institutions: Public health organizations, military medical facilities, and academic and government research institutions also represent significant customers, acquiring GE HealthCare's technologies for clinical care, public health initiatives, and scientific research.
As no specific customer companies are publicly identified as "major customers" by GE HealthCare, it is not possible to provide their names or stock symbols.
AI Analysis | Feedback
- NVIDIA (NVDA)
AI Analysis | Feedback
Peter Arduini, President and Chief Executive Officer
Peter Arduini serves as the President and CEO of GE HealthCare. Prior to this role, he was the President and Chief Executive Officer of Integra LifeSciences, where he significantly grew the company through organic growth and acquisitions. He also held various leadership positions at GE Healthcare earlier in his career.
Helmut Zodl, Chief Financial Officer
Helmut Zodl is the Chief Financial Officer of GE HealthCare. Before joining GE HealthCare, he served as the CFO of Baxter International Inc. Mr. Zodl has held senior finance leadership positions at various global companies, including Siemens Healthineers AG and Siemens AG.
Roland Rott, President and CEO, Imaging
Roland Rott is the President and CEO of the Imaging segment at GE HealthCare. He previously served as President & CEO of Ultrasound at GE HealthCare. Mr. Rott has a long tenure with GE HealthCare, holding various leadership positions and bringing extensive experience in the medical technology industry.
Kevin O'Neill, President and CEO, Pharmaceutical Diagnostics
Kevin O'Neill holds the position of President and CEO of Pharmaceutical Diagnostics at GE HealthCare. Prior to this role, he was the President and CEO of Medical Diagnostics at GE HealthCare. He possesses a strong background in the pharmaceutical and healthcare industry, having held numerous leadership roles.
Jan Makela, President and CEO, Ultrasound
Jan Makela serves as the President and CEO of Ultrasound at GE HealthCare. He previously held the role of President & CEO, Global Services at GE HealthCare. Mr. Makela has held multiple leadership positions within GE, including in the healthcare and power businesses, with a focus on global operations and strategic growth.
AI Analysis | Feedback
The key risks to GE HealthCare Technologies' business include intense competition and the need for continuous innovation, supply chain disruptions coupled with geopolitical and macroeconomic volatility, and stringent regulatory compliance alongside pressures to control healthcare costs.
1. Intense Competition and the Need for Continuous Innovation
GE HealthCare operates in highly competitive markets, facing significant rivals such as Siemens Healthineers and Philips. The company must continually invest in research and development (R&D) to keep pace with rapid technological advancements and evolving customer demands. For instance, GE HealthCare is currently playing catch-up in advanced areas like photon-counting CT technology. Failure to innovate or adapt quickly could lead to reduced market share and necessitate price reductions. Additionally, successful integration of AI and digital transformation initiatives carries execution risks.
2. Supply Chain Disruptions, Geopolitical Risks, and Macroeconomic Volatility
GE HealthCare is exposed to risks related to its global supply chain, including potential difficulties in obtaining components and raw materials, which could restrict manufacturing and increase costs. Geopolitical instability, such as tariff volatility, has already pressured the company's margins and guidance. Broader macroeconomic uncertainties, including economic downturns, public health crises, and fluctuations in foreign currency exchange rates, can adversely affect business operations and financial performance.
3. Regulatory Compliance and Healthcare Cost Control Pressures
The healthcare industry is subject to extensive and stringent global regulations. GE HealthCare must navigate diverse regulatory environments, and any lapses in compliance with laws like the Foreign Corrupt Practices Act (FCPA) could result in significant fines and reputational damage. Furthermore, industry-wide efforts to control healthcare costs often lead to lower reimbursements, which can negatively impact product demand and profitability. The company also faces the risk of becoming involved in various litigations and governmental proceedings.
AI Analysis | Feedback
The increasing consolidation and dominance of major technology companies (e.g., Google Health, Microsoft Health, Amazon Web Services) in developing and deploying large-scale AI-driven diagnostic platforms, data analytics, and cloud infrastructure for healthcare. These tech giants are actively integrating AI into various aspects of healthcare, from image analysis and predictive analytics to hospital operations and personalized medicine, often leveraging their vast computing power, data expertise, and established cloud ecosystems. While GE HealthCare is developing its own AI and digital solutions, the potential for these broader, platform-agnostic tech companies to become the primary "intelligence layer" for hospitals and healthcare systems represents a significant threat. This could commoditize GE HealthCare's hardware by reducing the value of its integrated proprietary AI and digital solutions, as healthcare providers increasingly rely on external, comprehensive AI platforms for their core diagnostic interpretation and data management needs.
AI Analysis | Feedback
GE HealthCare Technologies (GEHC) operates in several large and growing addressable markets for its main products and services. The company's total addressable market (TAM) was estimated at $84 billion globally in 2021 and is projected to reach approximately $100 billion by 2025. This market opportunity is further expanding, with some estimates putting it at over $110 billion globally.
Here's a breakdown of the addressable markets for GE HealthCare's key segments:
-
Imaging: The global medical imaging market size was approximately $40.33 billion in 2023 and is projected to grow to $70.19 billion by 2032, at a compound annual growth rate (CAGR) of 6.4%. Another estimate places the global market size at $41.64 billion in 2024, growing to $67.87 billion by 2034 with a CAGR of 4.99%. For 2025, the diagnostic imaging market is estimated at $48.92 billion globally, expected to reach $60.04 billion by 2030. In 2021, GE HealthCare estimated the Imaging industry size at $44 billion globally, with a projected CAGR of 4-6% from 2022-2025. North America holds a significant share, with the U.S. imaging services market valued at $133.76 billion in 2022 and forecast to reach around $216.84 billion by 2032. North America accounted for 41.02% of the diagnostic imaging market in 2024.
-
Ultrasound: The global ultrasound market is projected to grow from $8.9 billion in 2024 to $9.6 billion in 2025 and $16.0 billion by 2035, demonstrating a CAGR of 5.3%. Other estimates for the global ultrasound devices market include $9.12 billion in 2025, reaching $10.98 billion by 2030 at a CAGR of 3.77%. The market was valued at approximately $8.65 billion in 2023, with projections to reach $9.32 billion in 2024 and $13.87 billion by 2030, growing at a CAGR of 6.8%. In 2022, the global ultrasound devices market was valued at $9.3 billion and is projected to reach $15.4 billion by 2032. GE HealthCare identified the Ultrasound industry size as $10 billion globally in 2021, with a CAGR of 4-5% from 2022-2025. North America held the largest market share in 2022.
-
Patient Care Solutions: GE HealthCare reported the Patient Care Solutions (PCS) industry size as $12 billion globally in 2021, with a projected CAGR of 4-7% from 2022-2025. The global patient engagement solutions market, which includes aspects of patient care, was valued at $25.73 billion in 2024 and is projected to reach $109.02 billion by 2033, at a CAGR of 17.40%. Another source estimated the global patient engagement solutions market at $27.63 billion in 2024, expanding to $86.67 billion by 2030. North America held the dominant share of the global patient engagement solutions market in 2024, at 43.59%.
-
Pharmaceutical Diagnostics (PDx): The Pharmaceutical Diagnostics (PDx) industry size was estimated at $18 billion globally in 2021, with a CAGR of 3-6% projected from 2022-2025. GE HealthCare also refers to a $14 billion global end market for pharmaceutical diagnostics, growing at 7-9%. Specifically, the market for diagnostics and therapy in the prostate cancer space is a $9 billion market today, with an expectation to grow to $40 billion by 2032.
AI Analysis | Feedback
Here are 5 expected drivers of future revenue growth for GE HealthCare Technologies (GEHC) over the next 2-3 years:
- Innovation and Expansion of AI-powered Digital Health Solutions & New Product Launches: GE HealthCare is heavily investing in research and development to bring cutting-edge AI and digital solutions to market, including advanced imaging technologies, AI-powered diagnostic tools, and cloud-based platforms. The company is also focused on launching new, high-margin products, such as a full ultrasound platform refresh, new vascular offerings, next-generation MR and photon-counting CT systems, and advanced radiopharmaceuticals like Flyrcado™.
- Global Market Expansion, particularly in Emerging Markets: The company aims to broaden its global footprint, with a strategic focus on expanding into emerging markets where there is substantial growth potential for medical devices. This expansion is complemented by strong demand observed in established markets like the U.S. and the Europe, Middle East, and Africa (EMEA) regions.
- Sustained Growth in Pharmaceutical Diagnostics: The Pharmaceutical Diagnostics segment is a consistent driver of revenue, fueled by robust demand for contrast media, geographic expansion, and the introduction of new radiopharmaceutical products. This segment has consistently delivered high-single-digit or double-digit organic revenue growth.
- Strategic Acquisitions and Partnerships: GE HealthCare is actively pursuing strategic acquisitions and forming partnerships to strengthen its AI capabilities, expand its product portfolio, and increase its market penetration. Recent examples include the acquisitions of MIM Software and Intelligent Ultrasound's clinical AI business in 2023, and the planned acquisition of icometrix to bolster its position in Alzheimer's care.
- Expansion of Recurring Revenue Streams: The company is focused on increasing recurring revenue through the expansion of cloud-based solutions, aiming to triple its cloud-based offerings and grow digital revenue by approximately 50% through subscription-based models. Multi-year service agreements also contribute to a predictable revenue profile with high levels of predictability and accretive margins.
AI Analysis | Feedback
Share Repurchases
- GE HealthCare's Board of Directors authorized a share repurchase program of up to $1 billion of common stock in April 2025.
- The company reported $100 million in share buybacks over the period ending June 30, 2025.
Share Issuance
- Upon its spin-off from General Electric on January 4, 2023, approximately 454 million shares of common stock were issued to holders of GE's common stock.
Outbound Investments
- GE HealthCare's capital allocation priorities include increasing organic and inorganic investments to drive business growth.
Capital Expenditures
- GE HealthCare's capital expenditures averaged $316.6 million for fiscal years ending December 2020 to 2024.
- Reported capital expenditures were $387 million in 2023 and $401 million in 2024. The latest twelve months' capital expenditures were $430 million as of June 2025.
- Expected capital expenditures are $481.1 million for 2025 and $489 million for 2026, primarily focused on research and development to integrate AI into medical devices to enhance productivity, efficiency, and diagnostic confidence.
Latest Trefis Analyses
Trade Ideas
Select ideas related to GEHC.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02282026 | QDEL | QuidelOrtho | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 02272026 | CHE | Chemed | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02202026 | HAE | Haemonetics | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.5% | 3.5% | 0.0% |
| 02132026 | IQV | IQVIA | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 7.1% | 7.1% | -3.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 82.72 |
| Mkt Cap | 74.1 |
| Rev LTM | 15,934 |
| Op Inc LTM | 2,854 |
| FCF LTM | 1,998 |
| FCF 3Y Avg | 1,552 |
| CFO LTM | 2,509 |
| CFO 3Y Avg | 2,216 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 6.3% |
| Rev Chg 3Y Avg | 4.7% |
| Rev Chg Q | 8.4% |
| QoQ Delta Rev Chg LTM | 2.0% |
| Op Mgn LTM | 18.9% |
| Op Mgn 3Y Avg | 19.2% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 20.3% |
| CFO/Rev 3Y Avg | 19.9% |
| FCF/Rev LTM | 16.1% |
| FCF/Rev 3Y Avg | 15.8% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 74.1 |
| P/S | 3.7 |
| P/EBIT | 20.1 |
| P/E | 28.1 |
| P/CFO | 16.2 |
| Total Yield | 3.3% |
| Dividend Yield | 0.6% |
| FCF Yield 3Y Avg | 4.5% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -5.1% |
| 3M Rtn | -6.5% |
| 6M Rtn | -5.3% |
| 12M Rtn | -1.7% |
| 3Y Rtn | 13.4% |
| 1M Excs Rtn | -3.0% |
| 3M Excs Rtn | -6.9% |
| 6M Excs Rtn | -8.8% |
| 12M Excs Rtn | -22.9% |
| 3Y Excs Rtn | -60.3% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| ANDA215955 | REGADENOSON | regadenoson | solution | 8052024 | 6.7% | 7.4% | -13.1% | -7.0% | -7.0% |
| NDA212155 | CERIANNA | fluoroestradiol f-18 | solution | 5202020 | |||||
| ANDA210016 | CLARISCAN | gadoterate meglumine | solution | 11012019 | |||||
| NDA203137 | VIZAMYL | flutemetamol f-18 | injectable | 10252013 | |||||
| NDA022454 | DATSCAN | ioflupane i-123 | solution | 1142011 | |||||
| NDA022290 | ADREVIEW | iobenguane sulfate i-123 | solution | 9192008 | |||||
| NDA022066 | OMNISCAN | gadodiamide | injectable | 9052007 | |||||
Price Behavior
| Market Price | $72.73 | |
| Market Cap ($ Bil) | 32.9 | |
| First Trading Date | 01/04/2023 | |
| Distance from 52W High | -17.5% | |
| 50 Days | 200 Days | |
| DMA Price | $81.56 | $76.83 |
| DMA Trend | up | indeterminate |
| Distance from DMA | -10.8% | -5.3% |
| 3M | 1YR | |
| Volatility | 29.9% | 37.0% |
| Downside Capture | 134.05 | 157.82 |
| Upside Capture | 60.40 | 110.29 |
| Correlation (SPY) | 38.7% | 68.4% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.03 | 0.65 | 0.87 | 1.07 | 1.26 | 1.13 |
| Up Beta | -2.01 | -0.04 | -0.32 | 0.57 | 1.00 | 1.00 |
| Down Beta | 0.84 | 1.20 | 1.04 | 0.92 | 1.65 | 1.38 |
| Up Capture | 74% | 63% | 128% | 145% | 117% | 94% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 11 | 21 | 33 | 69 | 132 | 373 |
| Down Capture | -25% | 52% | 95% | 116% | 122% | 105% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 10 | 20 | 28 | 55 | 119 | 378 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GEHC | |
|---|---|---|---|---|
| GEHC | -15.9% | 37.0% | -0.39 | - |
| Sector ETF (XLV) | 4.0% | 17.5% | 0.07 | 61.4% |
| Equity (SPY) | 18.7% | 19.1% | 0.77 | 68.2% |
| Gold (GLD) | 79.6% | 26.2% | 2.22 | -0.3% |
| Commodities (DBC) | 19.2% | 17.2% | 0.88 | 18.5% |
| Real Estate (VNQ) | 5.3% | 16.4% | 0.14 | 56.4% |
| Bitcoin (BTCUSD) | -20.4% | 45.5% | -0.36 | 17.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GEHC | |
|---|---|---|---|---|
| GEHC | 3.9% | 31.7% | 0.22 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 48.7% |
| Equity (SPY) | 13.7% | 17.0% | 0.64 | 54.2% |
| Gold (GLD) | 24.5% | 17.2% | 1.16 | 7.4% |
| Commodities (DBC) | 11.6% | 19.0% | 0.50 | 13.6% |
| Real Estate (VNQ) | 5.3% | 18.8% | 0.19 | 43.8% |
| Bitcoin (BTCUSD) | 6.5% | 56.8% | 0.33 | 12.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with GEHC | |
|---|---|---|---|---|
| GEHC | 1.9% | 31.7% | 0.22 | - |
| Sector ETF (XLV) | 10.3% | 16.5% | 0.51 | 48.7% |
| Equity (SPY) | 14.9% | 17.8% | 0.72 | 54.2% |
| Gold (GLD) | 15.1% | 15.6% | 0.81 | 7.4% |
| Commodities (DBC) | 8.9% | 17.6% | 0.42 | 13.6% |
| Real Estate (VNQ) | 5.9% | 20.7% | 0.25 | 43.8% |
| Bitcoin (BTCUSD) | 66.0% | 66.8% | 1.05 | 12.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/4/2026 | 4.9% | 0.6% | -2.1% |
| 10/29/2025 | -2.5% | -6.4% | 1.5% |
| 7/30/2025 | -7.8% | -9.0% | -4.5% |
| 4/30/2025 | 3.3% | -1.5% | 5.1% |
| 2/13/2025 | 8.8% | 7.2% | -4.6% |
| 10/30/2024 | 2.3% | 3.4% | -2.7% |
| 7/31/2024 | 2.4% | -1.3% | 1.5% |
| 4/30/2024 | -14.3% | -10.3% | -11.8% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 6 | 6 |
| # Negative | 5 | 7 | 7 |
| Median Positive | 4.1% | 8.1% | 6.1% |
| Median Negative | -7.8% | -6.4% | -4.6% |
| Max Positive | 11.6% | 13.3% | 26.8% |
| Max Negative | -14.3% | -10.3% | -14.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/04/2026 | 10-K |
| 09/30/2025 | 10/29/2025 | 10-Q |
| 06/30/2025 | 07/30/2025 | 10-Q |
| 03/31/2025 | 04/30/2025 | 10-Q |
| 12/31/2024 | 02/13/2025 | 10-K |
| 09/30/2024 | 10/30/2024 | 10-Q |
| 06/30/2024 | 07/31/2024 | 10-Q |
| 03/31/2024 | 04/30/2024 | 10-Q |
| 12/31/2023 | 02/06/2024 | 10-K |
| 09/30/2023 | 10/31/2023 | 10-Q |
| 06/30/2023 | 07/25/2023 | 10-Q |
| 03/31/2023 | 04/25/2023 | 10-Q |
| 12/31/2022 | 02/15/2023 | 10-K |
| 09/30/2022 | 12/02/2022 | 10-12B/A |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.